U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C18H22N4O2
Molecular Weight 326.3929
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PEFICITINIB

SMILES

NC(=O)C1=C(N[C@H]2[C@H]3CC4C[C@@H]2C[C@@](O)(C4)C3)C5=C(NC=C5)N=C1

InChI

InChIKey=DREIJXJRTLTGJC-RRBRBRQDSA-N
InChI=1S/C18H22N4O2/c19-16(23)13-8-21-17-12(1-2-20-17)15(13)22-14-10-3-9-4-11(14)7-18(24,5-9)6-10/h1-2,8-11,14,24H,3-7H2,(H2,19,23)(H2,20,21,22)/t9?,10-,11+,14-,18+

HIDE SMILES / InChI

Molecular Formula C18H22N4O2
Molecular Weight 326.3929
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry MIXED
Additional Stereochemistry No
Defined Stereocenters 3 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Peficitinib (formerly known as ASP015K) is a pyrrolo[2,3-b]pyridine derivative orally administered once-daily JAK inhibitor in development for the treatment of Rheumatoid Arthritis. In preclinical studied Peficitinib inhibited JAK1 and JAK3 with IC50 of 3.9 and 0.7 nM, respectively. Peficitinib also inhibited IL-2-dependent T cell proliferation in vitro and STAT5 phosphorylation in vitro and ex vivo. Furthermore, Peficitinib dose-dependently suppressed bone destruction and paw swelling in an adjuvant-induced arthritis model in rats via prophylactic or therapeutic oral dosing regimens.In clinical trials, Peficitinib treatment prescribed at 50, 100 and 150 mg amounts each showed statistically significantly higher ACR20 response rates compared to the placebo and response rates increased up to the 150 mg dosage. Adverse events included neutropenia, headache, and abdominal pain. The treatment-emergent adverse events occurring more frequently in the Peficitinib group compared with the placebo group included diarrhea, nasopharyngitis, and increased serum creatine phosphokinase activity. No cases of serious infections were reported. Herpes zoster occurred in four patients (two each in the peficitinib 25 and 100 mg cohorts). The authors concluded that treatment with peficitinib as monotherapy for 12 weeks in Japanese patients with moderate to severe RA is efficacious and showed an acceptable safety profile.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
3.9 nM [IC50]
5.0 nM [IC50]
0.71 nM [IC50]
4.8 nM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Cmax

ValueDoseCo-administeredAnalytePopulation
373 ng/mL
100 mg 2 times / day steady-state, oral
[NO STEREO] PEFICITINIB plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
1380 ng × h/mL
100 mg 2 times / day steady-state, oral
[NO STEREO] PEFICITINIB plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
14.2 h
100 mg 2 times / day steady-state, oral
[NO STEREO] PEFICITINIB plasma
Homo sapiens

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
25 mg, 50 mg, 100 mg, or 150 mg once daily for 12 weeks.
Route of Administration: Oral
In Vitro Use Guide
Splenocytes from male Lewis rats were suspended in RPMI1640 (Sigma, St. Louis, MO, USA) supplemented with 10% fetal bovine serum and 50 mkM 2-mercaptoethanol at a density of 1.5 x 10^6 cells/mL. Rat splenocytes were cultured with Concanavalin A (Sigma) for 24 h at 37 C to induce IL-2 receptor expression. Splenocytes were then incubated with IL-2 (BD Biosciences, San Diego, CA, USA) and peficitinib or tofacitinib at designated concentrations in 96-well tissue culture plates. After 3-day incubation, alamarBlue® (Life Technologies, Carlsbad, CA, USA) was added to each of the test wells, followed by 4-6 h incubation. Fluorescence intensity was measured at an excitation wavelength of 545 nm and an emission wavelength of 590 nm.
Substance Class Chemical
Record UNII
HPH1166CKX
Record Status Validated (UNII)
Record Version